doi: 10.1016/0028-3908(86)90204-2.
Chlorisondamine blocks acquisition of the conditioned taste aversion produced by (-)-nicotine
- PMID: 3774129
- DOI: 10.1016/0028-3908(86)90204-2
Item in Clipboard
Chlorisondamine blocks acquisition of the conditioned taste aversion produced by (-)-nicotine
Neuropharmacology.
1986 Sep.
Abstract
Intraventricular microinjection (5 micrograms) of the bisquaternary ganglion-blocking drug chlorisondamine prevented acquisition of nicotine-induced conditioned taste aversion (CTA) in rats. This appeared to be a specific effect because chlorisondamine did not attenuate the conditioned taste aversion caused by apomorphine. These results support findings from other behavioural procedures indicating that centrally administered chlorisondamine causes a long-term blockade of central nicotinic mechanisms.
Similar articles
-
Intraneuronal accumulation and persistence of radiolabel in rat brain following in vivo administration of [3H]-chlorisondamine.Br J Pharmacol. 1995 Nov;116(5):2503-9. doi: 10.1111/j.1476-5381.1995.tb15102.x. Br J Pharmacol. 1995. PMID: 8581291 Free PMC article.
-
Chronic central nicotinic blockade after a single administration of the bisquaternary ganglion-blocking drug chlorisondamine.Br J Pharmacol. 1984 Oct;83(2):527-35. doi: 10.1111/j.1476-5381.1984.tb16517.x. Br J Pharmacol. 1984. PMID: 6148986 Free PMC article.
-
Conditioned aversion after delay place conditioning with nicotine.Psychopharmacology (Berl). 1987;92(3):376-81. doi: 10.1007/BF00210847. Psychopharmacology (Berl). 1987. PMID: 3114791
-
Pharmacologically specific pretreatment effects on apomorphine-mediated conditioned taste aversions in rats.Pharmacol Biochem Behav. 1984 Apr;20(4):507-11. doi: 10.1016/0091-3057(84)90296-x. Pharmacol Biochem Behav. 1984. PMID: 6728868
-
Nicotine affects ethanol-conditioned taste, but not place, aversion in a simultaneous conditioning procedure.Alcohol. 2018 Sep;71:47-55. doi: 10.1016/j.alcohol.2018.02.005. Epub 2018 Mar 2. Alcohol. 2018. PMID: 30029019 Free PMC article.
Cited by
-
The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion.Br J Pharmacol. 1994 Feb;111(2):397-405. doi: 10.1111/j.1476-5381.1994.tb14748.x. Br J Pharmacol. 1994. PMID: 7911713 Free PMC article.
-
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.Psychopharmacology (Berl). 1992;107(2-3):285-9. doi: 10.1007/BF02245149. Psychopharmacology (Berl). 1992. PMID: 1615127
-
Intraneuronal accumulation and persistence of radiolabel in rat brain following in vivo administration of [3H]-chlorisondamine.Br J Pharmacol. 1995 Nov;116(5):2503-9. doi: 10.1111/j.1476-5381.1995.tb15102.x. Br J Pharmacol. 1995. PMID: 8581291 Free PMC article.
-
Non-nicotine constituents in e-cigarette aerosol extract attenuate nicotine's aversive effects in adolescent rats.Drug Alcohol Depend. 2019 Oct 1;203:51-60. doi: 10.1016/j.drugalcdep.2019.05.023. Epub 2019 Aug 1. Drug Alcohol Depend. 2019. PMID: 31404849 Free PMC article.
-
Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro.Br J Pharmacol. 1994 Feb;111(2):406-13. doi: 10.1111/j.1476-5381.1994.tb14749.x. Br J Pharmacol. 1994. PMID: 8004384 Free PMC article.